The news of rate cuts from the European Central Bank (ECB) is giving traders more reason to short the euro.
This looks like a further step toward large-scale quantitative easing in the Eurozone, and the euro is likely to see devaluation at the hands of inflationary cues from the ECB.
Here’s how you should play this currency…
The news of rate cuts from the European Central Bank (ECB) is giving traders more reason to short the euro.
This looks like a further step toward large-scale quantitative easing in the Eurozone, and the euro is likely to see devaluation at the hands of inflationary cues from the ECB.
Here’s how you should play this currency…
This past week and a half saw all of The Big Three teen clothing retailers post a second consecutive quarter of year-over-year losses, further fueling the short selling spree on these specialty apparel retailers.
Abercrombie & Fitch Co. (NYSE: ANF), American Eagle Outfitters (NYSE: AEO), and Aeropostale Inc. (NYSE: ARO) have been suffering blows to their top line since the tail end of the recession, fueling short-selling activity that has further threatened these companies' stocks.
Here’s why they are struggling, and how to identify a prime retail short sale candidate.
The euro is readying for a substantial devaluation at the hands of oncoming monetary and fiscal stimulus.
But don't think the euro bears haven't already thought of that, as the currency has lost 5.3% since its peaks in May.
Here’s why the euro is worth a short, but also why you should wait before you dive in…
The case of ITT Educational Services Inc. (NYSE: ESI) proves that even in an ever-rising market, there are still companies posturing for a fall.
Already hampered by federal inquiries, the for-profit educational services firm has been drawing the short sellers in droves.
One of yesterday's (Wednesday) biggest stock gainers, Cerulean Pharma Inc. (Nasdaq: CERU), is a biotech company that posted a 30.6% gain by day's end.
This comes at a time when short sellers are adding to their positions, waiting for a downfall of biotech, and even the country's head central banker Janet Yellen has little faith in the sector. Biotech has been on a rally over the last year, a rally that a lot of traders feel has run its course.
But biotech is still strong, and here's why...
Bill Ackman's battle with Herbalife Ltd. (NYSE: HLF) has doomed the nutritional supplement maker's stock to bouts of wild volatility.
In just the last month HLF stock has dropped 11.2%, surged ahead 25.5%, fell another 26.8%, and finally advanced another 5%.
Here’s how it started and what’s been behind HLF stock’s recent rollercoaster ride…
GameStop stock (NYSE: GME) is a short selling favorite, and for good reason.
It's trying to navigate an online-centric marketplace as a physical retailer, and the short bets are playing off this knowledge to mount a strong position against the company.
But trying to profit off GME's downfall has proven harder than anticipated. Here's why...
This bull market has been raging on for five years, but the most savvy short sellers have found incredible profits.
You see, even when everything is going up in the market, there are still companies that are overvalued and have seen share-price losses this year.
In fact, short selling these five companies has been the right move in 2014...
Billionaire hedge fund manager Bill Ackman has called Herbalife's multi-level marketing model a "pyramid scheme" and has taken out an expensive bet against the company.
But other noted money managers like Carl Icahn are defending Herbalife (NYSE: HLF) and taking the other side of the bet, igniting a skirmish between short sellers and long buyers.
Herbalife Ltd. (NYSE: HLF) shares were down 12% in premarket trading with a second-quarter earnings release that missed analysts' expectations.
This all while the nutrition company continues to be a high-priced target for short sellers who are skeptical of HLF's marketing practices.
Here’s why this company is on everyone’s radar…
A five-year bull market is a tough time for short selling.
But even in these exuberant times, there is still room for the skeptic to make a profit betting on the downside.
Here's how - plus one short-selling winner that recent gave us 345% gains...
Everyone knows the U.S. housing "recovery" has been resurrected on slippery ground. But now that we're finally about to slip - big time - no one sees it coming...
Then again, how could they?
The numbers are incredibly misleading...
According to the Commerce Department, new residential home sales in July fell a whopping 13.4% from their June sales pace. And sales in April, May, and June were all revised significantly lower.
Yet according to the National Association of Realtors, existing home sales (completed transactions that include single-family homes, townhomes, condominiums, and co-ops) increased 6.5%... to a seasonally adjusted annual rate of 5.39 million in July, from a downwardly revised 5.06 million in June.
On the surface, the divergence is confusing. But not when you look below the surface, where the real money gets made.
As you'll see (before anyone else), the housing "recovery" is just one giant "short squeeze."
